iPSC-Derived Cardiomyocytes kit (AA,)
Applied StemCell has developed an efficient integration-free, small molecule-based method to differentiate high-quality cardiomyocytes from human iPSCs. The differentiated cardiomyocytes recapitulate the phenotype and functional parameters of primary and in vivo cardiomyocytes. We provide cardiomyocytes differentiated from an integration-free, control human iPSC line (ASE9211), reprogrammed from the fibroblasts of an African-American male donor. These high-purity (≥80%) cells beat in 2-3 days after recovery and express high levels of cTnT (Figure 1). These cryopreserved cardiomyocytes are ready-to-use in 2-3 days after recovery and are functionally viable for 7-14 days after recovery. To harness the full potential of our cardiomyocytes, we also provide optimized, serum-free Cardiomyocyte Culture Media (ASE-9703MM) and Cardiomyocyte Recovery Supplement A (1,000x) (ASE-9703MM-A) that supports robust maintenance and functionality of the cardiomyocytes in culture. These iPSC-differentiated cardiomyocytes can be used as control lines to compare phenotype and functionality of patient-derived, genome edited iPSC-derived cardiomyocytes for drug screening applications.
Reviews
There are no reviews yet.